Metsandia (Mometasone Furoate Monohydrate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene transcription to suppress inflammatory cytokine production, decrease immune cell infiltration, and reduce edema, leading to symptom relief.

The prescribed dose of Metsandia is determined by the treating physician. Typically, one spray per nostril once daily is recommended, but the exact regimen should follow the prescriber's instructions and the product label.

Safety data for Metsandia during pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women.

To order Metsandia, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Metsandia contains mometasone furoate, a high‑potency corticosteroid with a favorable safety profile when used as directed. Compared with lower‑potency agents such as fluticasone, it may achieve symptom control with once‑daily dosing, but choice of therapy depends on individual patient response and prescriber preference.

Metsandia should be stored at room temperature, below 25 °C, in its original packaging. Protect the spray from moisture and direct sunlight. Keep the device upright and avoid freezing.

Metsandia is administered as a nasal spray. The user gently shakes the bottle, inserts the tip into a nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks include adrenal suppression with prolonged high‑dose use, severe allergic reactions such as anaphylaxis, fungal infections of the nasal passages, and perforation of the nasal septum. Patients should seek medical attention if they experience unusual bleeding, persistent nasal pain, or systemic symptoms.

Metsandia is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active, untreated infections of the nasal mucosa or those who have recently undergone nasal surgery unless advised by a physician.